I've been predicting for some time that the regulatory requirements would lessen in the US as they took account of the unique properties of stem cell treatment, and the fact that the risks are many orders of magnitude lower, particularly in relation to patient safety. This has considerable implications in terms of lowered costs smaller trial groups and of course, faster regulatory acceptance.
This was scoffed at by the likes of madamswer, aatisket and fruitbat, (there were more but those are the most regular and loud contributors to the scoffing) but it has indeed proven to be the case.
For some reason their style of posting is always about short term 'emergencies' and the kind of thinking that works with drug companies who indeed have high risks. I can't think why they persist....
MSB Price at posting:
$1.30 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)